Matches in Wikidata for { <http://www.wikidata.org/entity/Q81071034> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q81071034 description "2008 թվականի ապրիլի 11-ին հրատարակված գիտական հոդված" @default.
- Q81071034 description "article scientifique publié en 2008" @default.
- Q81071034 description "artículu científicu espublizáu n'abril de 2008" @default.
- Q81071034 description "scientific article published on 11 April 2008" @default.
- Q81071034 description "wetenschappelijk artikel" @default.
- Q81071034 description "наукова стаття, опублікована у квітні 2008" @default.
- Q81071034 name "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 name "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 type Item @default.
- Q81071034 label "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 label "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 prefLabel "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 prefLabel "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 P1433 Q81071034-33902347-8846-4478-8048-31C428305109 @default.
- Q81071034 P1476 Q81071034-72464E53-1133-4AF1-B84F-514292E40451 @default.
- Q81071034 P2093 Q81071034-4E62075A-8958-4B93-8562-DFF6CC8CCF85 @default.
- Q81071034 P2093 Q81071034-8C3B4D28-7EC5-4E14-B712-E0FA0B5E99A9 @default.
- Q81071034 P2093 Q81071034-B61E5B70-88C3-49F4-9018-C317BDF8EF65 @default.
- Q81071034 P2093 Q81071034-E01873B4-EE47-443D-92E6-7B577FAB95B6 @default.
- Q81071034 P2093 Q81071034-E5FDCA8B-3C79-42F3-8D8F-23710AE0FC68 @default.
- Q81071034 P2860 Q81071034-562334F9-AF18-4F71-BECE-BD4AAA83EF09 @default.
- Q81071034 P304 Q81071034-03E76B05-F4CA-43F5-BC87-57D5665AFEF7 @default.
- Q81071034 P31 Q81071034-3AB1346B-B816-4F60-8A2E-DA3DAFC0769D @default.
- Q81071034 P356 Q81071034-75DC48DE-AE1D-4EC7-88B6-F531297B4C84 @default.
- Q81071034 P433 Q81071034-1220B22B-7765-472D-99A9-3E3E8D839050 @default.
- Q81071034 P478 Q81071034-E321A977-55F9-4171-B481-779012540DDB @default.
- Q81071034 P50 Q81071034-3C504E52-3A2F-41E3-B901-7D32D47A9D3A @default.
- Q81071034 P577 Q81071034-7F5A14EF-7CAF-4A66-A41F-34EB470793AF @default.
- Q81071034 P698 Q81071034-E799A6D7-9E8C-444E-B8C0-38AD9DA2811E @default.
- Q81071034 P921 Q81071034-11B07830-2C6A-424D-9C6E-9FA9B1C21D92 @default.
- Q81071034 P356 MDN163 @default.
- Q81071034 P698 18408222 @default.
- Q81071034 P1433 Q326122 @default.
- Q81071034 P1476 "Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment" @default.
- Q81071034 P2093 "G Salles" @default.
- Q81071034 P2093 "H Watier" @default.
- Q81071034 P2093 "M Ohresser" @default.
- Q81071034 P2093 "P Colombat" @default.
- Q81071034 P2093 "P Solal-Céligny" @default.
- Q81071034 P2860 Q104206347 @default.
- Q81071034 P304 "1485-1487" @default.
- Q81071034 P31 Q13442814 @default.
- Q81071034 P356 "10.1093/ANNONC/MDN163" @default.
- Q81071034 P433 "8" @default.
- Q81071034 P478 "19" @default.
- Q81071034 P50 Q38803376 @default.
- Q81071034 P577 "2008-04-11T00:00:00Z" @default.
- Q81071034 P698 "18408222" @default.
- Q81071034 P921 Q412323 @default.